- Home
- BTAI vs MGRX Comparison
BTAI vs MGRX Comparison
Compare BTAI & MGRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- MGRX
- Stock Information
- Founded
- BTAI 2017
- MGRX 2021
- Country
- BTAI United States
- MGRX United States
- Employees
- BTAI N/A
- MGRX N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- MGRX Computer Software: Prepackaged Software
- Sector
- BTAI Health Care
- MGRX Technology
- Exchange
- BTAI Nasdaq
- MGRX Nasdaq
- Market Cap
- BTAI 8.4M
- MGRX 8.1M
- IPO Year
- BTAI 2018
- MGRX 2023
- Fundamental
- Price
- BTAI $1.84
- MGRX $2.04
- Analyst Decision
- BTAI Buy
- MGRX
- Analyst Count
- BTAI 5
- MGRX 0
- Target Price
- BTAI $42.60
- MGRX N/A
- AVG Volume (30 Days)
- BTAI 436.1K
- MGRX 202.3K
- Earning Date
- BTAI 08-05-2025
- MGRX 05-15-2025
- Dividend Yield
- BTAI N/A
- MGRX N/A
- EPS Growth
- BTAI N/A
- MGRX N/A
- EPS
- BTAI N/A
- MGRX N/A
- Revenue
- BTAI $1,852,000.00
- MGRX $511,084.00
- Revenue This Year
- BTAI $5.03
- MGRX N/A
- Revenue Next Year
- BTAI $291.01
- MGRX N/A
- P/E Ratio
- BTAI N/A
- MGRX N/A
- Revenue Growth
- BTAI 5.47
- MGRX N/A
- 52 Week Low
- BTAI $1.17
- MGRX $1.32
- 52 Week High
- BTAI $25.92
- MGRX $7.66
- Technical
- Relative Strength Index (RSI)
- BTAI 64.53
- MGRX 52.44
- Support Level
- BTAI $1.17
- MGRX $2.05
- Resistance Level
- BTAI $1.48
- MGRX $2.28
- Average True Range (ATR)
- BTAI 0.13
- MGRX 0.24
- MACD
- BTAI 0.06
- MGRX 0.06
- Stochastic Oscillator
- BTAI 100.00
- MGRX 57.56
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.